Nicole Casasanta, MD
she/her/hers
InstructorAbout
Research
Publications
Featured Publications
TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer
Casasanta, N; Kahn, A; Fischbach, N; Pavlick, D, Lustberg, M; LoRusso, P; Sokol, E.S.; Graf, R; Quintanilha, J.C.F.; Li, G; Levy, M; Elvin, J; Ross, J.S.; & Pusztai, L. TP53 genomic alterations including targetable TP53 Y220C mutation in clinically advanced breast cancer.. JCO 43, 1043-1043(2025). DOI:10.1200/JCO.2025.43.16_suppl.1043Peer-Reviewed Original Research
2026
Homologous recombination deficiency signature (HRDsig+) in older women with advanced breast cancer (ABC).
Kaminski T, Casasanta N, Pavlick D, Saffern M, Sokol E, Sivakumar S, Gjoerup O, Ross J, Lustberg M. Homologous recombination deficiency signature (HRDsig+) in older women with advanced breast cancer (ABC). Journal Of Clinical Oncology 2026, 44: 1121-1121. DOI: 10.1200/jco.2026.44.16_suppl.1121.Peer-Reviewed Original ResearchAdvanced breast cancerTumor mutational burdenHomologous recombination deficiencyComprehensive genomic profilingCopy number changesGenomic alterationsBreast cancerOlder womenManagement of advanced breast cancerCombination of PARP inhibitorsTargeted therapy optionsHomologous recombination deficiency signatureMicrosatellite instabilityTumor suppressor genePD-L1Mutational burdenMSI-H statusMTAP lossRecombination deficiencyPARP inhibitorsAssociated with DNA repairTherapy optionsGenomic profilingSuppressor geneSignature statusPhase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial.
Kahn A, Du J, Schellhorn S, DiGiovanna M, Kidwai W, Rozenblit M, O'Neil D, Legare R, Casasanta N, Fischbach N, Fenn K, Blenman K, Ortiz C, Wei W, Maues J, Krop I, Winer E, Lustberg M, Pusztai L. Phase Ib randomized open-label trial of sacituzumab govitecan plus nivolumab or sacituzumab govitecan plus nivolumab and relatlimab as second-line therapy metastatic triple negative breast cancer: SIMONE trial. Journal Of Clinical Oncology 2026, 44: tps1164-tps1164. DOI: 10.1200/jco.2026.44.16_suppl.tps1164.Peer-Reviewed Original ResearchMetastatic triple-negative breast cancerTriple-negative breast cancerFixed Dose CombinationDose-limiting toxicitySacituzumab govitecanAntibody-drug conjugatesPD-L1Standard chemotherapyBreast cancerIncidence of dose-limiting toxicitiesEffector functionsStandard second-line therapyAnti-tumor immune responseFunction of exhausted T cellsTriple negative breast cancerClinical benefit rateFirst-line settingExhausted T cellsProgression-free survivalPhase Ib studySecond-line therapyDuration of responseCurative intent treatmentNegative breast cancerWithdrawal of consentAssociation of high and moderate penetrance monogenic variants, polygenic risk, and family history with breast cancer in an ancestrally diverse population
Soper E, Casasanta N, Dubois B, Belbin G, Kenny E, Abul-Husn N. Association of high and moderate penetrance monogenic variants, polygenic risk, and family history with breast cancer in an ancestrally diverse population. Cancer Genetics 2026, 304: 34-40. PMID: 41855952, DOI: 10.1016/j.cancergen.2026.03.004.Peer-Reviewed Original ResearchPolygenic risk scoresModerate penetrance genesElectronic health recordsBreast cancer riskPenetrance genesFamily historyCancer riskDegree of breast cancer riskBreast cancerElectronic health record reviewRisk of breast cancerLow polygenic risk scoresHigher polygenic risk scoresAncestrally diverse populationsDiverse populationsClinical genetic testingGenomic risk factorsHealth recordsPolygenic riskModify riskGenetic testingRisk scoreMonogenic variantsReduced riskRisk factors
2024
Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience
Patel R, Jin C, Jaber D, Casasanta N, Jain M, Fu W, Wu C, Moshier E, Tiersten A. Low Dose Tamoxifen for Breast Cancer Prevention: A Real-World Experience. Clinical Breast Cancer 2024, 25: 283-290. PMID: 39837695, DOI: 10.1016/j.clbc.2024.12.020.Peer-Reviewed Original ResearchConceptsLobular carcinoma in situDuctal carcinoma in situLow dose tamoxifenCarcinoma in situAtypical hyperplasiaBreast cancer preventionLog-binomial modelsRetrospective chart review of womenPoison regression modelsChart review of womenIncidence rate of AEFrequency of adverse eventsReview of womenCompare adverse event ratesRetrospective chart reviewHigh-risk lesionsAdverse event ratesCancer preventionIncidence rateAromatase inhibitorsAtypical lesionsAdverse eventsRegression modelsDisease characteristicsHyperplasiaCorrelating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
Casasanta N, Patel R, Raymond S, Kier M, Blanter J, Sohval S, Hovstadius M, Wu C, Zimmerman B, Cascetta K, Bagiella E, Tiersten A. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS). Clinical Breast Cancer 2024, 24: 585-596. PMID: 38971641, DOI: 10.1016/j.clbc.2024.06.005.Peer-Reviewed Original ResearchBreast Cancer IndexEarly-stage breast cancerOncotype DX RSAssociated with discordanceOncotype DX recurrence scoreAdjuvant therapy benefitReview of womenOncotype DXRecurrence scoreRecurrence riskEndocrine therapyCancer indexRetrospective chart review of womenChart review of womenRetrospective review of womenRisk of distant recurrenceTherapy benefitRisk of recurrenceRetrospective chart reviewRegression modelsUnivariate logistic regression modelLogistic regression modelsPrediction scoreDistant recurrenceAdjuvant therapy
2023
Outcomes with panobinostat in heavily pretreated multiple myeloma patients
Pan D, Mouhieddine T, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Seminars In Oncology 2023, 50: 40-48. PMID: 37005144, DOI: 10.1053/j.seminoncol.2023.03.006.Peer-Reviewed Original ResearchConceptsMultiple myelomaStandard-of-care therapyResponse rateTriple-class refractory diseaseHigh-risk cytogeneticsClinical benefit rateMedian overall survivalProgression-free survivalRefractory multiple myelomaMultiple myeloma patientsHistone-deacetylase inhibitorsDescending order of frequencyMount Sinai HospitalOral optionOverall survivalRefractory diseaseMyeloma patientsBenefit ratePanobinostatAcademic medical centerTriple classPatientsMyelomaAgent combinationsSinai Hospital
2022
Presentation of concurrent thrombotic thrombocytopenic purpura and Graves’ disease
Casasanta N, Shah N, Troy K, Edwards C, Patel R. Presentation of concurrent thrombotic thrombocytopenic purpura and Graves’ disease. Blood Coagulation & Fibrinolysis 2022, 33: 422-424. PMID: 35867945, DOI: 10.1097/mbc.0000000000001154.Peer-Reviewed Original ResearchConceptsThrombotic thrombocytopenic purpuraThrombocytopenic purpuraGraves' diseaseAutoimmune diseasesConcurrent thrombotic thrombocytopenic purpuraDeficient activity of ADAMTS13Retrospective review of patientsDiagnosing TTPUncontrolled autoimmune diseaseReview of patientsThyroid function testsAutoimmune thyroid diseaseActivity of ADAMTS13Thrombotic microangiopathyRetrospective reviewThyroid diseaseAutoimmune disordersStandard treatmentFunction testsDeficient activityPatientsThyrotoxicosisPurpuraDiseaseGraves
2019
Response to Letter to the Editor: High Oncotype DX Recurrence Score, Hereditary Cancer Syndromes, and Referral for Germline Genetic Testing
Casasanta N, Amdur R, Kaltman R. Response to Letter to the Editor: High Oncotype DX Recurrence Score, Hereditary Cancer Syndromes, and Referral for Germline Genetic Testing. Clinical Breast Cancer 2019, 20: e198-e199. PMID: 31964593, DOI: 10.1016/j.clbc.2019.12.007.Commentaries, Editorials and LettersRelationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score
Casasanta N, Kipnis S, Linville L, Lipinski S, Knoedler A, Marino A, McHenry A, Biagi T, Stark E, Amdur R, Denduluri N, Rodriguez P, Isaacs C, Kaltman R. Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score. Clinical Breast Cancer 2019, 20: 125-130. PMID: 31526714, DOI: 10.1016/j.clbc.2019.07.004.Peer-Reviewed Original ResearchConceptsGermline mutation statusOncotype DX recurrence scoreBreast cancer patientsRecurrence scoreMutation statusOncotype DXAssociation of RSGermline mutationsCancer patientsHormone receptor-positive breast cancer patientsHereditary cancer riskGermline genetic testingGenetic risk assessmentHereditary cancer syndromesAssociated with germline mutationsBenefit of chemotherapyRetrospective analysis of dataMultivariate logistic regression modelLikelihood of recurrenceFisher's exact testMultivariate logistic regressionCounseling of family membersLogistic regression modelsNon-BRCA1/2BRCA2 genes
Academic Achievements & Community Involvement
Clinical Care
Overview
Clinical Specialties
Medical Oncology; Breast Oncology
Board Certifications
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2023
News
News
- July 17, 2026Source: WTNH (with Nicole Casasanta, MD)
Best ways for cancer patients to stay cool during summer heat
- July 01, 2026
Dr. Nicole Casasanta Joins Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center
- December 13, 2025
Yale research advances presented at San Antonio Breast Cancer Symposium annual meeting
- June 06, 2025
Yale Cancer Center Researchers and Trainees Present at 2025 ASCO Annual Meeting
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.